Glenn Pierce on Overcoming Barriers to Gene Therapy in Hemophilia Care
“We published a reflective article on why the uptake of gene therapy in hemophilia is less than expected. It’s not due to lack of interest in gene therapy in general by patients and health care providers, as some have alleged, but related to more complex problems including the differing benefit/risk balance of individual gene therapies and need for more creative reimbursement frameworks. Medicines with strong efficacy and safety have been, and will continue to be embraced by the community. We look forward to advancing technological improvements in gene therapies, including gene editing, especially for hemophilia A, and to more enthusiasm of biopharma to reach 85% of the world having substandard or no treatment.”
To learn more, follow the link.
Read the full article here.
Article: Why is the uptake of gene therapy in hemophilia less than expected?
Authors:
Stay updated on the latest scientific advancements in the field of hemophilia with Hemostasis Today.
-
Feb 23, 2026, 17:59Wolfgang Miesbach: Real-World Evidence of Emicizumab on Joint Outcomes in Hemophilia A
-
Feb 23, 2026, 17:56Shiny K Kajal: The Transfusion Reaction We Often Miss
-
Feb 23, 2026, 17:53Radheshyam Meher: Contributing to the Transfusion Evidence Round-Up for International Childhood Cancer Day 2026
-
Feb 23, 2026, 17:46Mahesan Subramaniam: The Physiological Impact of Anger on Immunity
-
Feb 23, 2026, 17:42Bryan Fry: First Evidence That Bothrops atrox Venom Directly Activates Human Factor VII
-
Feb 23, 2026, 17:34Bastu Odoka: Why Blood Should NOT be Left at the Bedside to ‘Warm’
-
Feb 23, 2026, 17:28Henry Burkitt: Patients Are Challenging How the Medicines Policy System Works in England
-
Feb 23, 2026, 16:50Mutaz Al‑Sabah: Interesting Webinar on FH in Women is Now Available to Watch
-
Feb 23, 2026, 16:36Stéphanie Roullet։ New Method to Explore Primary Haemostasis in Cirrhotic Patients